Hypertension, or high blood pressure, is a chronic condition that significantly increases the risk of heart disease, stroke, and kidney failure. It accounts for approximately 1.28 billion cases globally among adults aged 30-79 years. There is a high unmet clinical need for better therapies, as current treatment options, such as ACE inhibitors and beta-blockers, have limitations. The rising focus on novel drug classes, including endothelin receptor antagonists and RNA-based therapies, is supporting pipeline growth. Emerging hypertension drug candidates, such as Firibastat and Aprocitentan, highlight the expanding therapeutic pipeline, promising more effective and targeted treatment options in the coming years.
Major companies involved in the hypertension pipeline drugs market include Insmed Incorporated, Bayer, and others.
Leading drugs currently in the pipeline include Adempas, Lorundrostat, Treprostinil Palmitil, and others.
The rising advancements in novel drug classes like endothelin receptor antagonists and RNA-based therapies are driving the growth of the hypertension drug pipeline, leading to more innovative and effective treatment options.
The Hypertension Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into hypertension therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hypertension. The hypertension report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hypertension pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hypertension treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hypertension.
Hypertension, or high blood pressure, occurs when blood exerts excessive force on artery walls. It results from genetics, obesity, high salt intake, stress, and inactivity. Over time, it damages blood vessels and increases the risk of heart disease, stroke, and kidney failure. Often symptomless, it is known as the "silent killer," making regular monitoring essential.
Hypertension is treated with lifestyle changes and medications. Diuretics, ACE inhibitors, beta-blockers, and calcium channel blockers help control blood pressure. A low-sodium diet, exercise, stress reduction, and weight management are crucial. In severe cases, combination therapies or newer drugs are used.
Hypertension affects an estimated 1.28 billion adults aged 30-79 worldwide. In the United States, approximately 120 million adults (48.1%) have hypertension, with 77.4% having uncontrolled cases. In England, 30% of adults are affected, including 15% with untreated hypertension. The Asia-Pacific region reports a prevalence of 10.6%-48.3%, with high-income nations like Japan reaching 48.3%, driving demand for advanced hypertension therapeutic products.
This section of the report covers the analysis of hypertension drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total hypertension clinical trials.
The drug molecule categories covered under the hypertension pipeline analysis include small molecules, monoclonal antibodies, peptides, gene therapies, RNA-based therapies, and others. The hypertension report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hypertension.
The EMR report for the hypertension drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hypertension therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hypertension clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hypertension. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hypertension drug candidates.
Riociguat, a guanylate cyclase stimulator, is currently undergoing Phase 4 clinical development. The RIALTO study, sponsored by Bayer, is evaluating the long-term benefits of Riociguat in patients with symptomatic pulmonary arterial hypertension (PAH) from previous Bayer trials. The study aims to assess patient outcomes and continued efficacy. With an estimated enrollment of 25 participants, it is expected to be completed by December 28, 2025.
Lorundrostat, an investigational drug, is being evaluated in a Phase 3 trial sponsored by Mineralys Therapeutics Inc. The trial is examining its blood pressure-lowering effects in patients on 2-5 antihypertensive medications. With around 1,083 participants, the trial is expected to conclude by February 2025, advancing treatment options for resistant hypertension.
Treprostinil Palmitil Inhalation Powder (TPIP) is being evaluated in a Phase 2b study sponsored by Insmed Incorporated. The study aims to assess the efficacy, safety, and pharmacokinetics of the drug in participants with pulmonary arterial hypertension. The study examines TPIP’s effect on pulmonary vascular resistance. Expected to be completed by July 31, 2025, it will involve approximately 102 participants in a randomized, double-blind, placebo-controlled trial.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Hypertension Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for hypertension. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hypertension collaborations, regulatory environments, and potential growth opportunities.
Global Idiopathic Intracranial Hypertension Treatment Market
Pulmonary Arterial Hypertension Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share